DOCSLIB.ORG

Who Are the Most Influential People in Vaccines? Blogs.Terrapinn.Com

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Who Are the Most Influential People in Vaccines? Blogs.Terrapinn.Com blogs.terrapinn.com/blogs.terrapinn.com/vaccinenationvaccinenation / Who are the most influential people in vaccines? blogs.terrapinn.com/ TOP 50 vaccine influencers vaccinenation Who are the most influential people in the global vaccines world? This is the question we asked our blog subscribers, LinkedIn group members and anyone in our contact network to compile a comprehensive list of the Top 50 as named by you. The following 50 personalities were picked based on their career achievements whether this was groundbreaking discovery and research or innovation, funding, lifetime dedication or simply because they might have inspired others to do well. It is great to see that we have representatives from all aspects including industry, governments, philanthropy, academia and even showbiz. Thank you to everyone who has helped us compile the list and please feel free to share it with your colleagues. blogs.terrapinn.com/ TOP 50 vaccine influencers 50 49 48 terrapinn.com/loyaltyasia vaccinenation No. 50 No. 49 No. 48 Rajeev Venkayya, Filip Dubovsky, Ewan McGregor, Executive Vice President, Vaccine Vice-President Clinical Development Actor and UNICEF Ambassador Business Division, Vaccines and Infectious Disease, Takeda MedImmune Ewan McGregor is on a mission to the ends of the earth to immunise some of the hardest-to- Dr. Venkayya is the Executive Vice President, Dr. Filip Dubovsky joined MedImmune in reach children in the world, following two Vaccine Business at Takeda Pharmaceuticals August 2006 as director, clinical vaccine trails, or 'cold chains', supported by International, overseeing Takeda’s global development and was named vice Unicef. vaccine enterprise Prior to this he was the president, clinical development, and Director of Vaccine Delivery at the Bill & global clinical therapeutic head, vaccines Melinda Gates Foundation, where he was in July 2008. In this capacity, he leads the responsible for the foundation’s top two vaccine clinical development programs priorities of polio eradication and new and the vaccine clinical activities for vaccine introduction, and investments of MedImmune's influenza franchise. Prior approximately $500 million/year. Dr. to joining MedImmune, Dr. Dubovsky held Venkayya was previously the Special several roles of increasing responsibility in Assistant to the President and Senior Director support of the Malaria Vaccine Initiative, for Biodefense at the White House. PATH. blogs.terrapinn.com/ TOP 50 vaccine influencers 47 46 45 terrapinn.com/loyaltyasia vaccinenation No. 50 No. 49 No. 48 Jon Kim Andrus, Pierre Morgon, Thomas Breuer, Chief, Immunization Unit Vice President, Franchise & Global Senior Vice President, Head of Pan American Health Organization Marketing Strategy Global Vaccine Development Sanofi Pasteur GSK Biologicals Dr. Jon Kim Andrus, a public health expert with Pierre Morgon has over 25 years experience Accountable for Department of 1200 25 years of experience of working in the field of in the pharmaceutical industry, in marketing people, covering Clinical R&D (phase I-IV), vaccines, immunization, and primary care in and operations positions as Product Epidemiology & Health Economics, Safety developing countries, has been named deputy Manager, International Group Product (Qualified Person Pharmacovigilance), director of the Pan American Health Manager, International Marketing Director, Medical Governance activities (including Organization, Regional Office for the Americas Vice President Marketing, VP Business Unit, Medical Compiance) as lead physician of the World Health Organization (PAHO/WHO). General Manager and VP Global Marketing (CMO) for Biologicals and regional Dr. Andrus has been serving as lead senior Operations. Medical Affairs activities. technical advisor for PAHO’s immunization Through these local and global positions, he program, where he has been a forceful advocate has acquired direct experience with for spreading the benefits of vaccination. blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology) and many geographies. blogs.terrapinn.com/ TOP 50 vaccine influencers 44 43 42 terrapinn.com/loyaltyasia vaccinenation No. 50 No. 49 No. 48 Jerald Sadoff, Peter Hotez, Dr Jean-Marie Okwo-Bele, Chief Medical Officer, President, Director of Immunization, Vaccines Crucell Sabin Vaccine Institute and Biologicals, WHO Before joining Crucell Dr. Sadoff was the Dr. Peter Hotez leads the Sabin Vaccine Dr Jean-Marie Okwo-Bele is responsible for President and Chief Executive Officer of Institute and Texas Children’s Hospital strategic direction, coordination and Aeras Global TB Vaccine Foundation. While at Center for Vaccine Development based at management of normative and programmatic Aeras, Dr. Sadoff developed the world's the Baylor College of Medicine in immunization activities. leading portfolio of TB vaccine candidates, Houston. His academic research focuses During his 27 years in public health, Dr Okwo- with two of the four candidates currently on vaccine development for a wide range Bele worked at country, regional and global being tested in Africa in Phase IIB efficacy of neglected tropical diseases around the levels in support of the expansion of childhood trials, built a strong network of development globe, as well as studies to increase immunization programmes, contributing to partnerships, and created a world-class awareness about the neglected tropical policy formulation, capacity building, vaccine manufacturing infrastructure. diseases in developing countries and in programme planning and evaluation, and Prior to jAeras Dr. Sadoff was the Executive the United States. disease surveillance. Director of Clinical Development of Vaccines . at Merck. blogs.terrapinn.com/ TOP 50 vaccine influencers 41 40 39 terrapinn.com/loyaltyasia vaccinenation No. 50 No. 49 Pedro Alonso, Stephen Cochi, Julie Gerberding, Director, Senior Advisor to the Director, President, Institute for Global Health of CDC Center for Global Health (CGH) Merck Vaccines Barcelona (ISGlobal) Stephen L. Cochi, MD, MPH, is Senior Advisor Dr. Julie Gerberding leads the company's Dr. Pedro Alonso started his career in to the Director, CDC Center for Global Health $5 billion global vaccine business. She is International Health 25 years ago as a (CGH), on Immunization and the Global responsible for the commercialization of physician working in West Africa. Since then Health Initiative, in addition to continuing his the current portfolio of vaccines, planning his work has focused in the key determinants role as Senior Advisor to the Director, Global for the introduction of vaccines from the of morbidity and mortality in the two most Immunization Division, National Center for company's robust vaccine pipeline, and vulnerable population groups in Africa: Immunization and Respiratory Diseases. accelerating Merck's on-going efforts to young children and pregnant women. broaden access to its vaccines in the Some of his most relevant work has been developing world. Dr. Gerberding led the carried out in malaria, leading to the Centers for Disease Control and development and testing of new control Prevention (CDC) as director from 2002 to tools for the prevention or treatment of P. 2009. During her tenure at CDC, Dr. falciparum. He has published more than 200 Gerberding led the agency during more papers in international peer reviewed than 40 emergency response initiatives. journals. blogs.terrapinn.com/ TOP 50 vaccine influencers 38 37 36 terrapinn.com/loyaltyasia vaccinenation No. 50 No. 49 Paulo Ernani Gadelha Vieira, Anthony Ford Hutchinson, Jos Vandelaer, President, (ex) Executive Vice President, Chief of Immunization, Oswaldo Cruz Foundation (Fiocruz) Merck UNICEF He has spent 30 years at Merck, starting in Bill Gates is co-chair of the Bill & Melinda Dr. Jos Vandelaer leads strategy 1981 when he joined Merck Frosst Canada in Gates Foundation. Along with co-chair development and program management Montreal, where he spent 17 years moving Melinda Gates, he shapes and approves and coordination. Dr. Vandelaer has been from Director of Pharmacology to Senior Vice grantmaking strategies, advocates for the working in immunization since 1996. President and Site Head. foundation’s issues, and helps set the overall Dr. Vandelaer has served as a Senior In 1998, Tony moved to Pennsylvania to direction of the organization. Health Specialist as a Global-level WHO head the basic research effort in the USA and Bill and Melinda Gates work together to focal point for the Neonatal Tetanus worldwide, covering all therapeutic areas. As expand opportunity to the world’s most Elimination program. He also advised on an Executive Vice President he became disadvantaged people by collaborating with immunization issues that included policy responsible for franchise strategies in grantees and partners. and strategy development, and provided multiple disease areas, including Vaccines scientific advice. and Infectious Diseases. Prior to that, Dr. Vandelaer had served in WHO as a Medical Officer in India, Philippines, and Myanmar. blogs.terrapinn.com/ TOP 50 vaccine influencers 35 34 33 terrapinn.com/loyaltyasia vaccinenation No. 50 No. 49 Christopher Elias, Wayne Koff, Christian Loucq, Senior Vice President and CSO, Director General, President, Global Development, Bill & Melinda Gates Foundation International Vaccine AIDS International Vaccine Institute Initiative Wayne C. Koff is an internationally Dr. Chris Elias leads the foundation’s efforts Dr. Loucq has over 30 years of professional
Load more

Recommended publications
  • Paul Offit: Claiming the High Gr Ound I N the Vaccine C Ontroversy
    PaUl oFFIt: CLAIMInG tHe HIGH GR oUnD I n tHe VaCCINE C ontRoVeRsY BY B rian G. Connell Y aul aul s my my a ourtesy c hen Paul Offit (Res ’80) was a resi- dent in the emergency department at / photo WChildren’s Hospital of Pittsburgh in RRIS the late 1970s, he had a patient—a 9-month- rank ha old infant—who died of rotavirus. Offit was f shocked to realize that this common intestinal infection still killed children in the United illustration States. A leading cause of severe diarrhea in Offit is co-inventor of the rotavirus vaccine RotaTeq, which was recommended for routine infants and young children, rotavirus contrib- immunizations in infants by the World Health Organization. utes to more than half a million deaths world- wide each year. have advanced the belief that there’s a link Offit, who has testified in congressional Some three decades later, in 2009, between vaccines and autism. The suspect hearings on vaccine safety, says the conse- RotaTeq— a vaccine for rotavirus—was recom- vaccines change, but the story remains the quences of skipping vaccines are not theo- mended by the World Health Organization to same: Citing anecdotes or data taken out of retical. He points to the pertussis outbreak in protect against the deadly infection. RotaTeq context, activist groups accuse physicians and California this year, which killed 10 infants is the fruit of 25 years of labor for Offit, the pharmaceutical companies of concealing what and infected 9,000 people. “We’re past the vaccine’s coinventor who is now a renowned they believe are harmful effects associated with tipping point,” he says.
    [Show full text]
  • NSABB June-July 2005 Meeting Agenda
    First Meeting of the National Science Advisory Board for Biosecurity June 30 – July 1, 2005 Hyatt Regency Bethesda 7400 Wisconsin Ave. Bethesda, Maryland, 20814 USA Hotel Phone: 301-657-1234 Agenda Webcast: To watch the live webcast of the meeting, click here. The webcast can only be viewed when the meeting is in session at 8:00am-6:00pm on June 30 and at 8:00am-1:30pm on July 1 Eastern Time. You will need RealOne Player to view the webcast. If you do not already have RealOne Player on your computer, download here. Presentation slides: To access the following PowerPoint presentations, click on the presentation titles below. June 30, 2005 Opening Remarks and Swearing in Ceremony Elias Zerhouni, M.D. Director of the National Institutes of Health (NIH) Chair's Remarks and Agenda Overview Dennis L. Kasper, M.D. NSABB Chair Harvard Medical School Introduction of NSABB Members NSABB Structure and Operations Thomas Holohan, M.D. NSABB Executive Director, NIH Office of Biotechnology Activities Break Perspectives on Biosecurity in the Life Sciences NSABB Voting Members Impetus for NSABB: Enhancing Biosecurity on the Life Sciences Rajeev Venkayya, M.D. Special Assistant to the President, Senior Director for Biological and Chemical Defense White House Homeland Security Council Perspectives on Biosecurity in the Life Sciences NSABB Ex Officio Members Lunch Session I- The Development of Criteria for Identifying Dual Use Research and Research Results Introduction: Issues of Relevance to Criteria Development Arturo Casadevall, M.D., Ph.D. Professor of Medicine and of Microbiology & Immunology and Chief of Infectious Diseases Albert Einstein College of Medicine National Research Council Perspective: Experiments of Concern Ron Atlas, Ph.D.
    [Show full text]
  • Myocarditis and Mrna Vaccines
    Updated June 28, 2021 DOH 348-828 Information for Clinical Staff: Myocarditis and mRNA Vaccines This document helps clinicians understand myocarditis and its probable link to some COVID-19 vaccines. It provides talking points clinicians can use when discussing the benefits and risks of these vaccines with their patients and offers guidance on what to do if they have a patient who presents with myocarditis following vaccination. Myocarditis information What are myocarditis and pericarditis? • Myocarditis is an inflammation of the heart muscle. • Pericarditis is an inflammation of the heart muscle covering. • The body’s immune system can cause inflammation often in response to an infection. The body’s immune system can cause inflammation after other things as well. What is the connection to COVID-19 vaccination? • A CDC safety panel has determined there is a “probable association” between myocarditis and pericarditis and the mRNA COVID-19 vaccines, made by Moderna and Pfizer-BioNTech, in some vaccine recipients. • Reports of myocarditis and pericarditis after vaccination are rare. • Cases have mostly occurred in adolescents and young adults under the age of 30 years and mostly in males. • Most patients who developed myocarditis after vaccination responded well to rest and minimal treatment. Talking Points for Clinicians The risk of myocarditis is low, especially compared to the strong benefits of vaccination. • Hundreds of millions of vaccine doses have safely been given to people in the U.S. To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email [email protected].
    [Show full text]
  • Michael S. Brown, MD
    DISTINGUISHED PHYSICIANS AND Michael S. Brown, M.D. Sir Richard Roberts, Ph.D. Winner, 1985 Nobel Prize in Physiology or Medicine Winner, 1993 Nobel Prize in Physiology or Medicine MEDICAL SCIENTISTS MENTORING Winner, 1988 Presidential National Medal of Science A globally prominent biochemist and molecular biologist, DELEGATES HAVE INCLUDED... Dr. Brown received the world’s most prestigious medical Dr. Roberts was awarded the Nobel Prize for his prize for his work describing the regulation of the groundbreaking contribution to discovering RNA splicing. cholesterol metabolism. His work laid the foundation for Dr. Roberts is dedicating his future research to GMO crops the class of drugs now called statins taken daily by more than 20 million and food sources, and demonstrating the effect they have on humanity. — GRANDg MASTERS — people worldwide. Ferid Murad, M.D., Ph.D. Mario Capecchi, Ph.D. Boris D. Lushniak, M.D., M.P.H Winner, 1998 Nobel Prize in Physiology or Medicine Academy Science Director The Surgeon General of the United States (acting, 2013-2014) Winner, 2007 Nobel Prize in Physiology or Medicine A world-renowned pioneer in biochemistry, Dr. Murad’s Winner, 2001 National Medal of Science Rear Admiral Lushniak, M.D., M.P.H., was the United award-winning research demonstrated that nitroglycerin Winner, 2001 Lasker Award States’ leading spokesperson on matters of public health, and related drugs help patients with heart conditions by Winner, 2003 Wolf Prize in Medicine overseeing the operations of the U.S. Public Health Service releasing nitric oxide into the body, thus relaxing smooth Mario Capecchi, Ph.D., a biophysicist, is a Distinguished Commissioned Corps, which consists of approximately muscles by elevating intracellular cyclic GMP, leading to vasodilation and Professor of Human Genetics at the University of Utah School of Medicine.
    [Show full text]
  • Presentation of Stanley Plotkin
    Vaccine Safety by Stanley A. Plotkin Advac Alumni 2019.pptx Sept. 22, 2019 Plotkin, Pediatrics, 2019; 143 2 (Cont.) 3 Vaccine Safety Library Topics May 2019 Heather Monk Bodenstab, PharmD, Paul Offit, MD, Frank DeStefano, MD • Adjuvants Other than Aluminum in Vaccines o Squalene (MF59, AS03, AF03) o Monophosphoryl lipid A (MPL), Saponin (QS21), and Related Adjuvant Systems (AS01, AS02, AS04) o CpG • Aluminum in Vaccines • Diabetes and Vaccines o Type-1 Diabetes o Gestational Diabetes • DNA and Vaccines • Egg Allergy and Vaccines o Influenza Vaccine o Measles-Containing Vaccine o Yellow Fever Vaccine • Guillain-Barre Syndrome (GBS) and Vaccines 4 Vaccine Safety Library Topics (cont.) May 2019 Heather Monk Bodenstab, PharmD, Paul Offit, MD, Frank DeStefano, MD • Human Papillomavirus (HPV) Vaccine Safety Concerns o HPV Vaccine and Chronic Fatigue Syndrome (CFS)/Systemic Exertion Intolerance Disease (SEID) o HPV Vaccine and Multiple Sclerosis/Central Demyelinating Disease o HPV Vaccine and Postural Orthostatic Tachycardia Syndrome (POTS) o HPV Vaccine and Primary Ovarian Insufficiency o HPV Vaccine and Promiscuity o HPV Vaccine and Venous Thromboembolism (VTE) • MMR and Autism • Multiple Sclerosis/Central Demyelinating Disease and Vaccines o Hepatitis B o Flu Vaccine • Pertussis Vaccine and Neurologic Complications • Pregnancy and Vaccines o HPV Vaccine and Pregnancy o Influenza Vaccine and Pregnancy o Pertussis-containing Vaccines and Pregnancy • Sudden-infant death syndrome (SIDS) and Vaccines • Thimerosal and Autism • Too Many, Too Soon • Vaccine Ingredients o Formaldehyde o Gelatin o Polysorbate 80 • Yeast and Vaccines 5 Package Insert for MMR Risks of a Vaccine Reaction . Soreness, redness, or rash where the shot is given and rash all over the body can happen after MMR vaccine.
    [Show full text]
  • COVID-19 Vaccine and CMT – Q & A
    COVID-19 Vaccine and CMT – Q & A Disclaimer: Nothing shared on these pages should be construed or is intended to be used for medical diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified health care provider. Should you have any emergency questions or concerns, please contact your physician or health care provider immediately. Always consult with your physician or other health care provider to gain clarification regarding any health care related questions. This content was sourced from the CDC, the CMTA Scientific Advisory Board, the MDA and the NY Times. What are the side effects of the COVID vaccine? Will they affect my CMT? The known side effects of current and likely-to-be authorized COVID-19 vaccines are similar to those of the annual influenza vaccine. These include symptoms such as: muscle soreness at the injection site, fever, tiredness, body aches and headache. It’s important to note that at this time we do not know whether or not the COVID-19 vaccine will have a different or more serious set of side effects for CMT patients. You should talk to your doctor about the possibility of more serious side effects of a COVID-19 vaccine for you. What impacts will the vaccine have on possible future gene therapy treatments or medications? Whether the vaccine will have an adverse impact on any course of treatment that you or your loved one may be taking is something that you will want to consult with your clinician about directly. Upon the FDA authorization of the Pfizer/BioNTech vaccine, the FDA did not name any contraindications pertaining to genetic therapies or other medications particularly important to the CMT community.
    [Show full text]
  • A Review of J. Craig Venter's a Life Decoded
    A peer-reviewed electronic journal published by the Institute for Ethics and Emerging Technologies ISSN 1541-0099 17(1) – March 2008 A review of J. Craig Venter’s A Life Decoded Randy Mayes, Duke University Journal of Evolution and Technology - Vol. 17 Issue 1 – March 2008 - pgs 71-72 http://jetpress.org/v17/mayes.htm In the early 1980s, a number of researchers suggested sequencing and mapping the human genome to help the science community better understand diseases and evolution. Following the announcement that the human genome had been sequenced, scientists wrote in peer-reviewed journals that we are not as hardwired as was once believed, and that the sequencing of the genome was just the beginning. Today, researchers have a new set of goals. In popular journalism, however, the science was lost in the shuffle. The media focused more on the dynamics of the conflicting philosophies of the private and public projects. This emphasis is also clear in the titles of several books chronicling the Human Genome Project, all appearing prior to the recent release of Craig Venter’s autobiography, A Life Decoded: My Genome: My Life (2007). Readers will find that Robert Cook-Deegan’s The Gene Wars (1995) and The Common Thread by Sir John Sulston and Georgina Ferry (2002), both written by insiders, are biased towards the philosophy of the public project, a commons approach. Sulston is a socialist who grows runner beans and drives a second hand car. By contrast, Venter travels in Lear jets and conducts business from his yacht. Three other books are more objective.
    [Show full text]
  • Immunization Pearls in This Issue
    DCIC Pearls Newsletter Print Immunization Pearls In this issue Membership meeting summary Immunizations in the news Stay Sharp- Educational Opportunities General Membership Meeting Summary Feb. 21, 2017 Jenny Kind (UHS) update on Mening B --most students immunized in fall did not receive 2nd dose at provider as recommended. Sally Zirbel Donish (MMSD)-partnership with DCIC, PHMDC and State grant made clinics possible Elizabeth Bourke (Deerfield School Nurse)--challenges of rural health and immunization access, particularly with 6th grade Tdap completion. Struggle with required Tdap coverage by exclusion deadline Dr. Conway-raised concerns of whether the school clinics sustainable. Public Health Prevention Fund at risk with serious impact on immunization programs and others as a result. Stay tuned.... Diane McHugh, PHMDC-- Coalition Engagement: School Based Clinics For complete meeting minutes and slides, see the DCIC website Save the Dates! DCIC Membership Meetings continue at the Madison Water Utility at 119 E. Olin Ave, Madison. Tuesdays from 12-1:30 on the following dates for 2017 DCIC Pearls Newsletter.html[6/15/2017 9:36:08 AM] DCIC Pearls Newsletter May 16 August 15 November 14 Immunization Update 2017 Wednesday April 5, 2017 5:00-6:00 pm Dinner 6:00-8:00 Presentation by Dr. Paul Hunter, "Adult Vaccine Update", followed by panel discussion of "Vaccine Hesitancy, from Babies to Boomers". American Family Insurance Education and Training Center 6000 American Pkwy Madison WI (between Sun Prairie and Madison) For health care staff who administer vaccines or facilitate administration. Registration has begun, seating is limited. Register soon. Information is posted on DCIC website.
    [Show full text]
  • Humankind 2.0: the Technologies of the Future 6. Biotech
    Humankind 2.0: The Technologies of the Future 6. Biotech Piero Scaruffi, 2017 See http://www.scaruffi.com/singular/human20.html for the full text of this discussion A brief History of Biotech 1953: Discovery of the structure of the DNA 2 A brief History of Biotech 1969: Jon Beckwith isolates a gene 1973: Stanley Cohen and Herbert Boyer create the first recombinant DNA organism 1974: Waclaw Szybalski coins the term "synthetic biology” 1975: Paul Berg organizes the Asilomar conference on recombinant DNA 3 A brief History of Biotech 1976: Genentech is founded 1977: Fred Sanger invents a method for rapid DNA sequencing and publishes the first full DNA genome of a living being Janet Rossant creates a chimera combining two mice species 1980: Genentech’s IPO, first biotech IPO 4 A brief History of Biotech 1982: The first biotech drug, Humulin, is approved for sale (Eli Lilly + Genentech) 1983: Kary Mullis invents the polymerase chain reaction (PCR) for copying genes 1986: Leroy Hood invents a way to automate gene sequencing 1986: Mario Capecchi performs gene editing on a mouse 1990: William French Anderson’s gene therapy 1990: First baby born via PGD (Alan Handyside’s lab) 5 A brief History of Biotech 1994: FlavrSavr Tomato 1994: Maria Jasin’s homing endonucleases for genome editing 1996: Srinivasan Chandrasegaran’s ZFN method for genome editing 1996: Ian Wilmut clones the first mammal, the sheep Dolly 1997: Dennis Lo detects fetal DNA in the mother’s blood 2000: George Davey Smith introduces Mendelian randomization 6 A brief History of Biotech
    [Show full text]
  • Background Information and Scientific Rationale
    Alternative Pneumococcal Vaccination Schedules for Infants in Fiji and Pneumococcal Epidemiology Dr Fiona Mary Russell Submitted in total fulfillment of the requirements of the degree of Doctor of Philosophy 11th October, 2010 Department of Paediatrics Faculty of Medicine, Dentistry, and Health Sciences The University of Melbourne i ABSTRACT This thesis documents the pneumococcal disease burden and the results of a Phase II pneumococcal vaccine trial in the low middle income country, Fiji. The overall objective was to gather sufficient evidence for the Fiji Ministry of Health to decide whether to introduce the pneumococcal vaccination into its national schedule and define an appropriate and affordable vaccination strategy. The nasopharynx is the main reservoir for pneumococci and plays an important role in the spread of the organism. Studies of nasopharyngeal carriage offer insights into the pneumococcal disease burden in a community, particularly for potential serotypes which may cause pneumonia, and are a convenient way of determining the level of antibiotic resistance among pneumococcal isolates circulating in a population. The first study, a cross- sectional pneumococcal nasopharyngeal carriage survey of healthy children aged 3–13 months, was undertaken to document the prevalence of pneumococcal nasopharyngeal carriage, risk factors for carriage, serotypes and antimicrobial susceptibility patterns of carried pneumococci in healthy young children in Fiji (Chapter 3). Pneumococcal nasopharyngeal carriage was common in Fijian children. Penicillin resistance was documented for the first time, and, as a result, first-line treatment for meningitis was altered. A low proportion of carriage serotypes were included in the 7-valent pneumococcal conjugate vaccine. Invasive pneumococcal disease is an important cause of morbidity and mortality, particularly in the very young and the elderly.
    [Show full text]
  • On Jim Watson's APOE Status: Genetic Information Is Hard to Hide
    European Journal of Human Genetics (2009) 17, 147–150 & 2009 Macmillan Publishers Limited All rights reserved 1018-4813/09 $32.00 www.nature.com/ejhg LETTERS 15.6 (95% CI, 10.9–22.5) and 4.3 (95% CI, 3.3–5.5) for APOE e4 homozygotes and e4/e3 heterozygotes respectively, 6 On Jim Watson’s APOE compared to e3 homozygotes. The meta-analytic odds ratios in population-based Caucasian samples were 11.8 status: genetic (95% CI, 7.0–19.8) and 2.8 (95% CI, 2.3–3.5), respec- tively.6 In a large Rotterdam (Netherlands), population- information is hard to based prospective study of people aged 55 years or above, it hide was estimated that 17% of the overall risk of AD could be attributed to the e4 allele, with 3% (95% CI, 0–6%) of cases attributed to the e4/e4 genotype, and 14% (95% CI, 7–21%) European Journal of Human Genetics (2009) 17, 147–149; 7 to the e4/e3 genotype. doi:10.1038/ejhg.2008.198; published online 22 October 2008 A recent investigation of LD for 50 SNPs in and surrounding APOE in 550 Caucasians identified multiple SNPs in the TOMM40 gene B15 kb upstream of APOE, and The recent publication and release to public databases of at least one SNP in the other surrounding genes LU, PVRL2, Dr James Watson’s sequenced genome,1 with the exception APOC1, APOC4 and CLPTM1 were associated with LOAD of all gene information about apolipoprotein E (ApoE), risk.8 In particular, the C allele of SNP rs157581 in provides a pertinent example of the challenges concerning TOMM40 is in strong LD (r240.6) with the C allele of privacy and the complexities of informed consent in the rs429358 in APOE, which defines the e4 allele.
    [Show full text]
  • VACCINE TECHNOLOGY II: Conference Program
    Program VACCINE TECHNOLOGY II June 1-6, 2008 Grande Real Santa Eulalia Resort Albufeira, Algarve, Portugal Co-Chairs: Barry C. Buckland, Ph.D. Research Vice President, Bioprocess R&D, Merck & Co., Inc. John G. Auniņš, Ph.D. Executive Scientific Director, Bioprocess R&D, Merck & Co., Inc. Paula Marques Alves, Ph.D. Principal Investigator Animal Cell Technology Laboratory, ITQB/IBET Kathrin U. Jansen, Ph.D. Sr. Vice President Early Phase Programs, Wyeth Vaccine Research Engineering Conferences International 6 MetroTech Center Brooklyn, NY 11201, USA Phone: 1-718-260-3743, Fax: 1-718-260-3754 www.engconfintl.org - [email protected] Organizing Committee Manuel Carrondo, Professor and CEO, IBET, Portugal Manon Cox, COO, Protein Sciences Corp., USA Matthew Croughan, Professor, Keck Graduate Institute, USA Anne De Groot, CEO, EpiVax, Inc., USA Emilio Emini, Executive Vice President, Wyeth Pharmaceuticals, USA Nathalie Garçon, Vice President, GlaxoSmithKline Biologicals, Belgium Phillip Gomez, Principal, PRTM, USA Michael Hoare, Professor, University College London, UK David Kaslow, Vice President, Merck & Co., Inc., USA Phil Minor, Head, Division of Virology, NIBSC, UK Octavio Ramirez, Professor, Institute of Biotechnology, UNAM, Mexico Rino Rappuoli, Vice President, Novartis Vaccines, Italy Jerald Sadoff, CEO, Aeras Global TB Vaccine Foundation, USA Volker Sandig, Vice President, ProBioGen AG, Germany George Siber, Consultant, USA John Vose, Consultant, France David Weiner, Professor, University of Pennsylvania School of Medicine, USA Sunday, June 1, 2008 03:30 pm – 05:30 pm Registration 05:30 pm – 06:00 pm Welcome and conference overview 06:00 pm – 07:00 pm The Challenge of Providing an Effective, but Technically Complex, Vaccine to the Developing World Emilio Emini, Wyeth Pharmaceuticals, USA 07:00 pm – 08:00 pm Reception 08:00 pm – 10:00 pm Opening Dinner and entertainment IMPORTANT ANNOUNCEMENTS • Audiotaping, videotaping and photography of presentations are strictly prohibited.
    [Show full text]